Related references
Note: Only part of the references are listed.Pharmacodynamic effects during the transition between cangrelor and prasugrel
David J. Schneider et al.
CORONARY ARTERY DISEASE (2015)
Pharmacodynamic Effects During the Transition Between Cangrelor and Ticagrelor
David J. Schneider et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2014)
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials
Dominick J. Angiolillo et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2012)
Cangrelor: a novel P2Y12 receptor antagonist
Nicholas B. Norgard
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Intravenous Platelet Blockade with Cangrelor during PCI.
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Platelet Inhibition with Cangrelor in Patients Undergoing PCI.
Robert A. Harrington et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function
N. L. Dovlatova et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect
Steven R. Steinhubl et al.
THROMBOSIS RESEARCH (2008)
Share Paper
